| (210) | Number of the EPO application | 22162349 |
| (220) | Filing date of the EPO application | 2017.09.29 |
| (80) | EPO patent specification publication (B) | EPB nr. 14/2025, 2025.04.02 |
| (110) | EPO patent number | 4094766 |
| (21) | Number of the application | e 2023 0658 |
| (71) | Name(s) of applicant(s), code of the country | Sumitomo Pharma Switzerland GmbH, CH;
Takeda Pharmaceutical Company Limited, JP; |
| (72) | Name(s) of inventor(s), code of the country | JOHNSON Brendan Mark, US;
SEELY Lynn, US;
MUDD Paul N. Jr., US;
WOLLOWITZ Susan, US;
HIBBERD Mark, GB;
TANIMOTO Masataka, JP;
RAJASEKHAR Vijaykumar Reddy, US;
SUKHATME Mayukh Vasant, US; |
| (73) | Name(s) of owner(s), code of the country | Sumitomo Pharma Switzerland GmbH, CH;
Takeda Pharmaceutical Company Limited, JP; |
| (54) | Title of the invention | ORAL FIXED DOSE COMBINATION AND USE THEREOF IN THE TREATMENT OF UTERINE FIBROIDS AND ENDOMETRIOSIS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/513 (2006.01.01); A61K 31/565 (2006.01.01); A61K 31/57 (2006.01.01); A61P 15/00 (2006.01.01) |
| (19) | Country | CH |
| (41) | Date of publication of the application | 2023.07.31 |
| (30) | Priority | 201662402034 P, 2016.09.30, US; 201662402055 P, 2016.09.30, US; 201662402150 P, 2016.09.30, US; 201762492839 P, 2017.05.01, US; 201762528409 P, 2017.07.03, US |